A new study showed that the breast cancer drug Herceptin improved survival in patients with HER2-positive stomach cancer, an aggressive form of the disease. The study (called the ToGA study) was led by Eric Van Cutsem, a professor at the University Hospital Gasthuisberg, Leuven, Belgium and was presented at the annual meeting of the American Society of Clinical Oncology which is being held in Orlando Floriday from 29 May to 2 June.
More...
Linear Mode
